Raloxifene/SBE-β-CD Inclusion Complexes Formulated into Nanoparticles with Chitosan to Overcome the Absorption Barrier for Bioavailability Enhancement
Raloxifene (RXF) is a hormone-like medication used for treating postmenopausal osteoporosis and estrogen-dependent breast cancer, yet associated with bad low bioavailability due to poor solubility. This study was intended to develop cyclodextrin/chitosan nanoparticles (ccNPs) for oral delivery of RX...
Saved in:
Main Authors: | Zaihua Wang (Author), Yan Li (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2018-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Enhanced oral bioavailability and anticancer efficacy of fisetin by encapsulating as inclusion complex with HPβCD in polymeric nanoparticles
by: Amrita Kadari, et al.
Published: (2017) -
Development and characterization of solid lipid nanoparticles for enhancement of oral bioavailability of Raloxifene
by: B Divyakant Patel, et al.
Published: (2012) -
RP-HPLC simultaneous quantification of rutin, avobenzone, and octyl methoxycinnamate in the presence of hydroxypropyl β-cyclodextrin (HPβCD) and sulfobutyl ether β-cyclodextrin (SBEβCD)
by: Tércio Elyan Azevedo Martins, et al.
Published: (2023) -
Human serum albumin-based nanoparticles alter raloxifene administration and improve bioavailability
by: Shu-Jyuan Yang, et al.
Published: (2022) -
Thymoquinone-entrapped chitosan-modified nanoparticles: formulation optimization to preclinical bioavailability assessments
by: Iqra Rahat, et al.
Published: (2021)